Cargando…

Human papillomavirus infection and lung adenocarcinoma: special benefit is observed in patients treated with immune checkpoint inhibitors

BACKGROUND: Human papilloma virus (HPV) has been associated with the development and modulation of response in a series of neoplasms. In the case of lung adenocarcinoma, its role in etiology and pathogenesis is still controversial. Considering that this infection brings foreign epitopes, it could be...

Descripción completa

Detalles Bibliográficos
Autores principales: Rojas, L., Mayorga, D., Ruiz-Patiño, A., Rodríguez, J., Cardona, A.F., Archila, P., Avila, J., Bravo, M., Ricaurte, L., Sotelo, C., Arrieta, O., Zatarain-Barrón, Z.L., Carranza, H., Otero, J., Vargas, C., Barrón, F., Corrales, L., Martín, C., Recondo, G., Pino, L.E., Bermudez, M.A., Gamez, T., Ordoñez-Reyes, C., García-Robledo, J.E., de Lima, V.C., Freitas, H., Santoyo, N., Malapelle, U., Russo, A., Rolfo, C., Rosell, R.
Formato: Online Artículo Texto
Lenguaje:English
Publicado: Elsevier 2022
Materias:
Acceso en línea:https://www.ncbi.nlm.nih.gov/pmc/articles/PMC9434139/
https://www.ncbi.nlm.nih.gov/pubmed/35753086
http://dx.doi.org/10.1016/j.esmoop.2022.100500
_version_ 1784780803900702720
author Rojas, L.
Mayorga, D.
Ruiz-Patiño, A.
Rodríguez, J.
Cardona, A.F.
Archila, P.
Avila, J.
Bravo, M.
Ricaurte, L.
Sotelo, C.
Arrieta, O.
Zatarain-Barrón, Z.L.
Carranza, H.
Otero, J.
Vargas, C.
Barrón, F.
Corrales, L.
Martín, C.
Recondo, G.
Pino, L.E.
Bermudez, M.A.
Gamez, T.
Ordoñez-Reyes, C.
García-Robledo, J.E.
de Lima, V.C.
Freitas, H.
Santoyo, N.
Malapelle, U.
Russo, A.
Rolfo, C.
Rosell, R.
author_facet Rojas, L.
Mayorga, D.
Ruiz-Patiño, A.
Rodríguez, J.
Cardona, A.F.
Archila, P.
Avila, J.
Bravo, M.
Ricaurte, L.
Sotelo, C.
Arrieta, O.
Zatarain-Barrón, Z.L.
Carranza, H.
Otero, J.
Vargas, C.
Barrón, F.
Corrales, L.
Martín, C.
Recondo, G.
Pino, L.E.
Bermudez, M.A.
Gamez, T.
Ordoñez-Reyes, C.
García-Robledo, J.E.
de Lima, V.C.
Freitas, H.
Santoyo, N.
Malapelle, U.
Russo, A.
Rolfo, C.
Rosell, R.
author_sort Rojas, L.
collection PubMed
description BACKGROUND: Human papilloma virus (HPV) has been associated with the development and modulation of response in a series of neoplasms. In the case of lung adenocarcinoma, its role in etiology and pathogenesis is still controversial. Considering that this infection brings foreign epitopes, it could be of prognostic significance in patients with lung adenocarcinoma treated with immunotherapy. METHODS: In a retrospective cohort study we evaluated the presence of HPV genomic material in lung adenocarcinoma primary lesions with the INNO-LiPA platform. Viral replication was also evaluated by detecting the presence of oncoprotein E6/E7 messenger RNA (mRNA) by quantitative RT-PCR. To confirm possible hypotheses regarding viral oncogenesis, vascular endothelial growth factor (VEGF) and hypoxia-inducible factor 1 (HIF1) were evaluated with stromal fibrosis and immunoscore. RESULTS: A total of 133 patients were included in the analysis, of whom 34 tested positive for HPV, reaching an estimated prevalence of 25.6% [95% confidence interval (CI) 18.2% to 32.9%]. E6/7 mRNA was identified in 28 out of the 34 previously positive cases (82.3%). In immune checkpoint inhibitor (ICI)-treated patients, the median overall survival reached 22.3 months [95% CI 19.4 months- not reached (NR)] for HPV-negative and was not reached in HPV-positive (HPV+) ones (95% CI 27.7-NR; P = 0.008). With regard to progression-free survival, HPV− patients reached a median of 9.2 months (95% CI 7.9-11.2 months) compared to 14.3 months (95% CI 13.8-16.4 months) when HPV was positive (P = 0.001). The overall response rate for HPV+ patients yielded 82.4% compared to 47.1% in negative ones. No differences regarding programmed death-ligand 1, VEGF, HIF1, stromal fibrosis, or immunoscore were identified. CONCLUSIONS: In patients with HPV+ lung adenocarcinoma, a significant benefit in overall response and survival outcomes is observed.
format Online
Article
Text
id pubmed-9434139
institution National Center for Biotechnology Information
language English
publishDate 2022
publisher Elsevier
record_format MEDLINE/PubMed
spelling pubmed-94341392022-09-02 Human papillomavirus infection and lung adenocarcinoma: special benefit is observed in patients treated with immune checkpoint inhibitors Rojas, L. Mayorga, D. Ruiz-Patiño, A. Rodríguez, J. Cardona, A.F. Archila, P. Avila, J. Bravo, M. Ricaurte, L. Sotelo, C. Arrieta, O. Zatarain-Barrón, Z.L. Carranza, H. Otero, J. Vargas, C. Barrón, F. Corrales, L. Martín, C. Recondo, G. Pino, L.E. Bermudez, M.A. Gamez, T. Ordoñez-Reyes, C. García-Robledo, J.E. de Lima, V.C. Freitas, H. Santoyo, N. Malapelle, U. Russo, A. Rolfo, C. Rosell, R. ESMO Open Original Research BACKGROUND: Human papilloma virus (HPV) has been associated with the development and modulation of response in a series of neoplasms. In the case of lung adenocarcinoma, its role in etiology and pathogenesis is still controversial. Considering that this infection brings foreign epitopes, it could be of prognostic significance in patients with lung adenocarcinoma treated with immunotherapy. METHODS: In a retrospective cohort study we evaluated the presence of HPV genomic material in lung adenocarcinoma primary lesions with the INNO-LiPA platform. Viral replication was also evaluated by detecting the presence of oncoprotein E6/E7 messenger RNA (mRNA) by quantitative RT-PCR. To confirm possible hypotheses regarding viral oncogenesis, vascular endothelial growth factor (VEGF) and hypoxia-inducible factor 1 (HIF1) were evaluated with stromal fibrosis and immunoscore. RESULTS: A total of 133 patients were included in the analysis, of whom 34 tested positive for HPV, reaching an estimated prevalence of 25.6% [95% confidence interval (CI) 18.2% to 32.9%]. E6/7 mRNA was identified in 28 out of the 34 previously positive cases (82.3%). In immune checkpoint inhibitor (ICI)-treated patients, the median overall survival reached 22.3 months [95% CI 19.4 months- not reached (NR)] for HPV-negative and was not reached in HPV-positive (HPV+) ones (95% CI 27.7-NR; P = 0.008). With regard to progression-free survival, HPV− patients reached a median of 9.2 months (95% CI 7.9-11.2 months) compared to 14.3 months (95% CI 13.8-16.4 months) when HPV was positive (P = 0.001). The overall response rate for HPV+ patients yielded 82.4% compared to 47.1% in negative ones. No differences regarding programmed death-ligand 1, VEGF, HIF1, stromal fibrosis, or immunoscore were identified. CONCLUSIONS: In patients with HPV+ lung adenocarcinoma, a significant benefit in overall response and survival outcomes is observed. Elsevier 2022-06-23 /pmc/articles/PMC9434139/ /pubmed/35753086 http://dx.doi.org/10.1016/j.esmoop.2022.100500 Text en © 2022 The Authors https://creativecommons.org/licenses/by-nc-nd/4.0/This is an open access article under the CC BY-NC-ND license (http://creativecommons.org/licenses/by-nc-nd/4.0/).
spellingShingle Original Research
Rojas, L.
Mayorga, D.
Ruiz-Patiño, A.
Rodríguez, J.
Cardona, A.F.
Archila, P.
Avila, J.
Bravo, M.
Ricaurte, L.
Sotelo, C.
Arrieta, O.
Zatarain-Barrón, Z.L.
Carranza, H.
Otero, J.
Vargas, C.
Barrón, F.
Corrales, L.
Martín, C.
Recondo, G.
Pino, L.E.
Bermudez, M.A.
Gamez, T.
Ordoñez-Reyes, C.
García-Robledo, J.E.
de Lima, V.C.
Freitas, H.
Santoyo, N.
Malapelle, U.
Russo, A.
Rolfo, C.
Rosell, R.
Human papillomavirus infection and lung adenocarcinoma: special benefit is observed in patients treated with immune checkpoint inhibitors
title Human papillomavirus infection and lung adenocarcinoma: special benefit is observed in patients treated with immune checkpoint inhibitors
title_full Human papillomavirus infection and lung adenocarcinoma: special benefit is observed in patients treated with immune checkpoint inhibitors
title_fullStr Human papillomavirus infection and lung adenocarcinoma: special benefit is observed in patients treated with immune checkpoint inhibitors
title_full_unstemmed Human papillomavirus infection and lung adenocarcinoma: special benefit is observed in patients treated with immune checkpoint inhibitors
title_short Human papillomavirus infection and lung adenocarcinoma: special benefit is observed in patients treated with immune checkpoint inhibitors
title_sort human papillomavirus infection and lung adenocarcinoma: special benefit is observed in patients treated with immune checkpoint inhibitors
topic Original Research
url https://www.ncbi.nlm.nih.gov/pmc/articles/PMC9434139/
https://www.ncbi.nlm.nih.gov/pubmed/35753086
http://dx.doi.org/10.1016/j.esmoop.2022.100500
work_keys_str_mv AT rojasl humanpapillomavirusinfectionandlungadenocarcinomaspecialbenefitisobservedinpatientstreatedwithimmunecheckpointinhibitors
AT mayorgad humanpapillomavirusinfectionandlungadenocarcinomaspecialbenefitisobservedinpatientstreatedwithimmunecheckpointinhibitors
AT ruizpatinoa humanpapillomavirusinfectionandlungadenocarcinomaspecialbenefitisobservedinpatientstreatedwithimmunecheckpointinhibitors
AT rodriguezj humanpapillomavirusinfectionandlungadenocarcinomaspecialbenefitisobservedinpatientstreatedwithimmunecheckpointinhibitors
AT cardonaaf humanpapillomavirusinfectionandlungadenocarcinomaspecialbenefitisobservedinpatientstreatedwithimmunecheckpointinhibitors
AT archilap humanpapillomavirusinfectionandlungadenocarcinomaspecialbenefitisobservedinpatientstreatedwithimmunecheckpointinhibitors
AT avilaj humanpapillomavirusinfectionandlungadenocarcinomaspecialbenefitisobservedinpatientstreatedwithimmunecheckpointinhibitors
AT bravom humanpapillomavirusinfectionandlungadenocarcinomaspecialbenefitisobservedinpatientstreatedwithimmunecheckpointinhibitors
AT ricaurtel humanpapillomavirusinfectionandlungadenocarcinomaspecialbenefitisobservedinpatientstreatedwithimmunecheckpointinhibitors
AT soteloc humanpapillomavirusinfectionandlungadenocarcinomaspecialbenefitisobservedinpatientstreatedwithimmunecheckpointinhibitors
AT arrietao humanpapillomavirusinfectionandlungadenocarcinomaspecialbenefitisobservedinpatientstreatedwithimmunecheckpointinhibitors
AT zatarainbarronzl humanpapillomavirusinfectionandlungadenocarcinomaspecialbenefitisobservedinpatientstreatedwithimmunecheckpointinhibitors
AT carranzah humanpapillomavirusinfectionandlungadenocarcinomaspecialbenefitisobservedinpatientstreatedwithimmunecheckpointinhibitors
AT oteroj humanpapillomavirusinfectionandlungadenocarcinomaspecialbenefitisobservedinpatientstreatedwithimmunecheckpointinhibitors
AT vargasc humanpapillomavirusinfectionandlungadenocarcinomaspecialbenefitisobservedinpatientstreatedwithimmunecheckpointinhibitors
AT barronf humanpapillomavirusinfectionandlungadenocarcinomaspecialbenefitisobservedinpatientstreatedwithimmunecheckpointinhibitors
AT corralesl humanpapillomavirusinfectionandlungadenocarcinomaspecialbenefitisobservedinpatientstreatedwithimmunecheckpointinhibitors
AT martinc humanpapillomavirusinfectionandlungadenocarcinomaspecialbenefitisobservedinpatientstreatedwithimmunecheckpointinhibitors
AT recondog humanpapillomavirusinfectionandlungadenocarcinomaspecialbenefitisobservedinpatientstreatedwithimmunecheckpointinhibitors
AT pinole humanpapillomavirusinfectionandlungadenocarcinomaspecialbenefitisobservedinpatientstreatedwithimmunecheckpointinhibitors
AT bermudezma humanpapillomavirusinfectionandlungadenocarcinomaspecialbenefitisobservedinpatientstreatedwithimmunecheckpointinhibitors
AT gamezt humanpapillomavirusinfectionandlungadenocarcinomaspecialbenefitisobservedinpatientstreatedwithimmunecheckpointinhibitors
AT ordonezreyesc humanpapillomavirusinfectionandlungadenocarcinomaspecialbenefitisobservedinpatientstreatedwithimmunecheckpointinhibitors
AT garciarobledoje humanpapillomavirusinfectionandlungadenocarcinomaspecialbenefitisobservedinpatientstreatedwithimmunecheckpointinhibitors
AT delimavc humanpapillomavirusinfectionandlungadenocarcinomaspecialbenefitisobservedinpatientstreatedwithimmunecheckpointinhibitors
AT freitash humanpapillomavirusinfectionandlungadenocarcinomaspecialbenefitisobservedinpatientstreatedwithimmunecheckpointinhibitors
AT santoyon humanpapillomavirusinfectionandlungadenocarcinomaspecialbenefitisobservedinpatientstreatedwithimmunecheckpointinhibitors
AT malapelleu humanpapillomavirusinfectionandlungadenocarcinomaspecialbenefitisobservedinpatientstreatedwithimmunecheckpointinhibitors
AT russoa humanpapillomavirusinfectionandlungadenocarcinomaspecialbenefitisobservedinpatientstreatedwithimmunecheckpointinhibitors
AT rolfoc humanpapillomavirusinfectionandlungadenocarcinomaspecialbenefitisobservedinpatientstreatedwithimmunecheckpointinhibitors
AT rosellr humanpapillomavirusinfectionandlungadenocarcinomaspecialbenefitisobservedinpatientstreatedwithimmunecheckpointinhibitors
AT humanpapillomavirusinfectionandlungadenocarcinomaspecialbenefitisobservedinpatientstreatedwithimmunecheckpointinhibitors